Literature DB >> 1782983

Oxidative polymorphism of dextromethorphan in a Burundi population.

F Nsabiyumva1, Y Furet, E Autret, A P Jonville, M Breteau.   

Abstract

The wide availability, metabolism by the same cytochrome P450 as debrisoquine and, above all, the inocuity of dextromethorphan (DMP) favour the frequent choice of this drug as the test substance in determining oxidation phenotypes. 100 healthy Burundian volunteers (94 m and 6 f) in this study ingested 50 mg DMP bromhydrate, i.e. 38.5 mg of DMP base. Urine was collected for 8 h following the dose and TLC was used to analyse it. The method was particularly useful in view of its low cost, speed and the ease of applying it to a large study group. 5% of the Burundian subjects were poor metabolizers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782983     DOI: 10.1007/BF00280112

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.

Authors:  P Dayer; T Leemann; R Striberni
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

2.  Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.

Authors:  D K Sommers; J Moncrieff; J Avenant
Journal:  Hum Toxicol       Date:  1988-05

3.  Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

Authors:  N M Woolhouse; M Eichelbaum; N S Oates; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

4.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

Authors:  L Bertilsson; A Aberg-Wistedt; L L Gustafsson; C Nordin
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

6.  Debrisoquine oxidative phenotyping and psychiatric drug treatment.

Authors:  F Derenne; C Joanne; S Vandel; G Bertschy; R Volmat; P Bechtel
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.

Authors:  W E Evans; M V Relling; W P Petros; W H Meyer; J Mirro; W R Crom
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

8.  Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography.

Authors:  Y H Park; M P Kullberg; O N Hinsvark
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

9.  Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

Authors:  M Hildebrand; W Seifert; A Reichenberger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Simplified phenotyping with dextromethorphan by thin-layer chromatography: application to clinical laboratory screening for deficiencies in oxidative drug metabolism.

Authors:  R J Guttendorf; P J Wedlund; J Blake; S L Chang
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

View more
  1 in total

1.  Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers.

Authors:  Yali Shen; Zhu Luo; Qin Yu; Ying Wang; Jin Xiang; Jia Miao
Journal:  Eur J Clin Pharmacol       Date:  2017-02-28       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.